A new combination of Factor Xa inhibition and standard antiplatelet therapy to prevent more recurrent cardiovascular events after ACS
With an unrestricted educational grant from BAYER HEALTHCARE PHARMACEUTICALS
Presentations available when logged in:
- Introduction and objectives
- Thrombin generation and its critical long-term role post ACS - Combining Rivaroxaban 2.5mg BID and standard antiplatelet therapy to reduce atheroth...
- Case presentations - Complex NSTE-ACS case and STEMI ACS case: management of patients at high ischaemic risk and low bleeding risk
- Rivaroxaban clinical trial programme: proven experience and new clinical activities in cardiology
- Take-home message